Pathstone Family Office’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $4.38M | Buy |
64,744
+14,964
| +30% | +$1.01M | 0.03% | 295 |
|
|
2023
Q2 | $3.57M | Sell |
49,780
-3,284
| -6% | -$236K | 0.05% | 213 |
|
|
2023
Q1 | $3.68M | Sell |
53,064
-68,682
| -56% | -$4.76M | 0.06% | 183 |
|
|
2022
Q4 | $8.97M | Buy |
121,746
+28,715
| +31% | +$2.12M | 0.08% | 187 |
|
|
2022
Q3 | $5.12M | Buy |
93,031
+67,868
| +270% | +$3.73M | 0.05% | 229 |
|
|
2022
Q2 | $1.66M | Buy |
25,163
+3,237
| +15% | +$214K | 0.04% | 237 |
|
|
2022
Q1 | $1.46M | Sell |
21,926
-400
| -2% | -$26.7K | 0.03% | 238 |
|
|
2021
Q4 | $1.3M | Buy |
22,326
+1,625
| +8% | +$94.6K | 0.03% | 273 |
|
|
2021
Q3 | $1.24M | Buy |
20,701
+4,534
| +28% | +$272K | 0.04% | 237 |
|
|
2021
Q2 | $968K | Buy |
16,167
+4,268
| +36% | +$256K | 0.03% | 278 |
|
|
2021
Q1 | $592K | Buy |
11,899
+9,405
| +377% | +$468K | 0.02% | 310 |
|
|
2020
Q4 | $125K | Buy |
2,494
+1,984
| +389% | +$99.4K | 0.01% | 341 |
|
|
2020
Q3 | $28K | Hold |
510
| – | – | ﹤0.01% | 434 |
|
|
2020
Q2 | $27K | Hold |
510
| – | – | ﹤0.01% | 386 |
|
|
2020
Q1 | $23K | Sell |
510
-749
| -59% | -$33.8K | ﹤0.01% | 399 |
|
|
2019
Q4 | $627K | Buy |
1,259
+749
| +147% | +$373K | 0.01% | 256 |
|
|
2019
Q3 | $23K | Hold |
510
| – | – | ﹤0.01% | 372 |
|
|
2019
Q2 | $21K | Hold |
510
| – | – | ﹤0.01% | 434 |
|
|
2019
Q1 | $21K | Buy |
+510
| New | +$21K | ﹤0.01% | 426 |
|
|
2016
Q3 | – | Sell |
-250
| Closed | -$8K | – | 200 |
|
|
2016
Q2 | $8K | Buy |
+250
| New | +$8K | 0.01% | 154 |
|